Ignite Creation Date:
2025-12-24 @ 3:04 PM
Ignite Modification Date:
2026-01-04 @ 6:52 AM
Study NCT ID:
NCT02571959
Status:
COMPLETED
Last Update Posted:
2018-01-12
First Post:
2015-04-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D019980', 'term': 'Amoxicillin-Potassium Clavulanate Combination'}, {'id': 'D000658', 'term': 'Amoxicillin'}], 'ancestors': [{'id': 'D019818', 'term': 'Clavulanic Acid'}, {'id': 'D002969', 'term': 'Clavulanic Acids'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000667', 'term': 'Ampicillin'}, {'id': 'D010400', 'term': 'Penicillin G'}, {'id': 'D010406', 'term': 'Penicillins'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 36}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-07-24', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-01', 'completionDateStruct': {'date': '2017-06-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-01-11', 'studyFirstSubmitDate': '2015-04-14', 'studyFirstSubmitQcDate': '2015-10-07', 'lastUpdatePostDateStruct': {'date': '2018-01-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-10-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-10-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Systematic plasmatic clearance (Cl)', 'timeFrame': '1 day'}], 'secondaryOutcomes': [{'measure': 'Area under the curve time - concentration (AUC 0-oo)', 'timeFrame': '1 day'}, {'measure': 'Half-life time (T1/2)', 'timeFrame': '1 day'}, {'measure': 'Volume of distribution (Vd)', 'timeFrame': '1 day'}, {'measure': 'Bioavailability after oral administration (F)', 'timeFrame': '1 day'}, {'measure': 'Constant of speed of absorption (Ka)', 'timeFrame': '1 day'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Obesity', 'Pharmacology', 'Amoxicillin-Potassium Clavulanate Combination'], 'conditions': ['Obesity']}, 'descriptionModule': {'briefSummary': "Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration Determination of the pharmacokinetic parameters of amoxicillin / clavulanic acid obtained from plasmatic concentrations of intravenous injection (IV) and oral administrations. The criterion of evaluation allowing to answer our main objective corresponds to the parameters estimated by the pharmacokinetic model of the concentrations obtained from the data IV and by the pharmacokinetic model of the concentrations obtained from the oral data. The following pharmacokinetic parameters will be considered at every obese volunteer's for both molecules (amoxicillin and clavulanic acid) from the concentrations by pharmacokinetic analysis of population.\n\nThe main evaluation criteria are PK parameters of amoxicillin / clavulanic:\n\n* Cl, systematic plasmatic clearance\n* Vd, volume of distribution\n* ASC 0-oo, area under the curve time - concentration\n* T1/2, half-life time\n* F, bioavailability after oral administration\n* Ka, constant of speed of absorption", 'detailedDescription': "Main objective Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration\n\nSecondary objectives\n\n* Define dosage plans optimized with the antibiotic treatment to the obese subject\n* Ensure an adequacy of the treatment with the related infection\n* Formulate recommendations of dosage adaptations for a better individualization of treatments, by estimating several plans of doses by simulation to reach various PK/PD goals according to different theoretical MIC\n\nMethodology\n\nThe pharmacokinetic analysis will be realized by approach of population allowing the estimation of the average parameters of amoxicillin and clavulanic acid as well as the interpersonal variability after an administration IV and an oral administration. Parameters's population and their variability will be estimated with the SAEM algorithm implemented in the software Monolix ( www.lixoft.eu ).\n\nFor the main objective, PK parameters PK of amoxicillin and clavulanic acid will be determined to day 1 and day 2. They will be described by means of indicators of position (average and median) and of dispersal (standard deviations, quartiles).\n\nFor secondary objectives, the profiles concentration/time of 1000 obese subjects will be determined by Monte Carlo method from PK parameters estimated at the balance by the model. For every feigned profile, the time during which the plasmatic concentration of amoxicillin and clavulanic acid is superior to a panel of theoretical MIC will be calculated by means of curves concentration - time determined for each of the subjects."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Voluntary obese\n* Body mass index upper to 30 kg/m2\n* Age from 18 to 65 years\n* Signed free and lit consent\n* Possible participation according to the national file of the volunteers of the French Ministry of Health.\n* Volunteers affiliated to the Social Security\n\nExclusion Criteria:\n\n* Pregnancy\n* Evolutionary pregnancy or feeding\n* Allergy in ß-lactamines (nettle rash, oedema of Quincke)\n* Digestive intolerance with amoxicillin / clavulanic acid\n* Infection by the virus of the HIV ( positive Ac anti HIV)\n* Infection by the virus of the hepatitis B ( positive Ag Hbs)\n* Infection by the virus of the hepatitis C ( positive Ac anti VHC)\n* Hepatic cirrhosis at the Child-Pugh C stage(stadium)\n* Biological parameters:\n* Polynucléaires neutrophiles 750 / mm3\n* Haemoglobin 8g / dL\n* Patellets 60 000 / mm3\n* Creatinin clearance, according to MDRD, DFG 50 mL / min / 1,73m2\n* ASAT or ALAT \\> 3 times the superior limit of the normal (LSN)\n* Phosphatase alkaline \\> 3 LSN\n* Total Bilirubine \\> 3 LSN\n* Lipase \\> 3 LSN\n* Factor V \\< 50 %\n* Alcoholism chronicles (consumption superior to 30 g of alcohol a day, amount to 3 glasses of wine)\n* Significant anomaly of the electrocardiogram, in particular QTc \\> 450 msec\n* Subject susceptible not to respect the modalities of the study\n* Drug addiction intra venous\n* Any medical conditions which according to the judgment(sentence) of the investigator would may interfere with the moderate pharmacokinetic parameters\n* People placed under legal protection\n* Histories of bariatric surgery'}, 'identificationModule': {'nctId': 'NCT02571959', 'acronym': 'PHACO', 'briefTitle': 'Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults', 'organization': {'class': 'OTHER', 'fullName': "Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba"}, 'officialTitle': 'Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)', 'orgStudyIdInfo': {'id': 'IMEA 046'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'amoxicillin and clavulanic acid', 'description': 'All volunteers receive a dose of amoxicillin and clavulanic acid', 'interventionNames': ['Drug: amoxicillin and clavulanic acid']}], 'interventions': [{'name': 'amoxicillin and clavulanic acid', 'type': 'DRUG', 'otherNames': ['AMOXICILLINE / acide clavulonique SANDOZ'], 'description': 'Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered', 'armGroupLabels': ['amoxicillin and clavulanic acid']}, {'name': 'amoxicillin and clavulanic acid', 'type': 'DRUG', 'otherNames': ['AMOXICILLINE / acide clavulonique SANDOZ'], 'description': 'Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route', 'armGroupLabels': ['amoxicillin and clavulanic acid']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92100', 'city': 'Boulogne', 'country': 'France', 'facility': 'Hopital Ambroise Pare', 'geoPoint': {'lat': 46.79346, 'lon': -1.3194}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba", 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}